Adicet Bio

Cash, cash equivalents and short‑term treasuries were $137.6 million at March 31, 2026, with management stating runway into 2H 2027. Q1 2026 net loss was $20.2 million; R&D was $17.5 million and G&A $4.1 million. Total liabilities were ~$29.3 million; shares outstanding were 9.60 million at March 31, 2026 (9.35 million as of May 11, 2026).

The company executed a 1‑for‑16 reverse split on December 30, 2025 and raised ~$74.8 million net in October 2025. Balance sheet quality is reasonable for a clinical‑stage biotech, but the company remains capital‑markets dependent until commercialization or substantial partnerships are secured.